Physician profile
Quinton E Moss
NPI 1306993985
$629,271.91
in general payments reported to CMS, 2019-2025
31 companies · $234K in 2025
The $234K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $73K · 2020: $44K · 2021: $63K · 2022: $35K · 2023: $70K · 2024: $110K · 2025: $234K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $320K · Honoraria: $36K · Travel and Lodging: $34K · Food and Beverage: $17K · Consulting Fee: $7,461 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $319,936.90 |
| Honoraria | $36,114.00 |
| Travel and Lodging | $33,523.88 |
| Food and Beverage | $17,018.38 |
| Consulting Fee | $7,461.00 |
| Education | $245.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $159,470.08 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $147,923.93 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $106,594.08 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $93,329.74 | 2019-2025 | Vivitrol, Vivitrol, Aristada |
| Allergan, INC. | $56,521.42 | 2019-2021 | |
| Axsome Therapeutics, INC. | $39,505.81 | 2022-2025 | Auvelity |
| Indivior INC. | $11,552.33 | 2019-2025 | Sublocade, Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $7,493.72 | 2020-2025 | Caplyta |
| Neuronetics, INC. | $1,439.88 | 2019-2024 | Neurostar Tms Therapy System |
| Sunovion Pharmaceuticals INC. | $905.88 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $878.60 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $821.31 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $656.13 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $549.87 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $518.42 | 2019-2024 | Rexulti, Abilify Maintena |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $238.83 | 2023-2025 | Brixadi |
| Idorsia Pharmaceuticals US INC | $136.51 | 2023 | Quviviq |
| Avanir Pharmaceuticals, INC. | $132.89 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $88.77 | 2019-2024 | Trintellix |
| Almatica Pharma LLC | $85.44 | 2025 | Loreev Xr |
| Corium, LLC | $74.96 | 2023-2025 | Azstarys |
| Biogen, INC. | $63.09 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $53.51 | 2021-2024 | Rejoyn |
| Noven Therapeutics, LLC | $51.57 | 2020-2024 | Secuado |
| Ironshore Pharmaceuticals INC. | $36.13 | 2023-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $36.00 | 2025 | Qelbree |
| Tempus Ai, INC | $30.34 | 2024 | |
| Tris Pharma INC | $29.34 | 2024 | Dyanavel Xr |
| Eisai INC. | $22.43 | 2020 | |
| Uswm, LLC | $17.65 | 2022 | |
| Shire North American Group INC | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Quinton Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.